RAPT Therapeutics Inc

NASDAQ:RAPTUnited States

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, it develops selective small molecules designed to modulate the critical immune responses underlying these diseases. Its lead inflammation drug candidate, zelnecirnon (RPT193), and its lead oncology drug candidate, tivumecirnon (FLX475), each target C-C motif chemokine receptor 4 (CCR4), a drug target that potentially has broad applicability in inflammatory diseases and oncology. Its inflammation drug candidate, zelnecirnon, is designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its oncology drug candidate, tivumecirnon, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors.

Contact Information

Headquarters

561 Eccles AveSOUTH SAN FRANCISCO, CA, United States 94080-1906

Phone

650-489-9000

Fax

302-531-3150

Executives

Independent Chairman of the Board

William Rieflin

President, Chief Executive Officer, Director

Brian Wong

Chief Financial Officer

Rodney Young

Chief Scientific Officer

Dirk Brockstedt

Chief Medical Officer

William Ho